# US 2021/0332020 A1 · Phenylsulfonylurea derivatives useful as nlrp3 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332020 A1
- Document ID: US20210332020A1
- Status: Published application
- Kind: A1
- Application number: 16/977,239
- Filed: 2019-03-01
- Published: 2021-10-28
- Earliest claimed: 2018-03-02
- Assignees: Inflazome Limited
- Applicants: Inflazome Limited
- Inventors: Matthew COOPER; David MILLER; Angus MACLEOD
- Web page: https://patentgrep.com/patent/US20210332020A1

## CPC

- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 311/60: having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07D 213/34: to which a second hetero atom is attached
- C07C 2603/10: containing five-membered rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
Q is selected from O or S;
R1 is selected from (i) a monovalent group comprising an aryl or a heteroaryl group, or (ii) a monovalent group comprising a heterocyclic group, wherein the heterocyclic group contains at least one nitrogen atom in its ring structure;
R2 is a 6-membered cyclic group substituted at the 2- and 4-positions, wherein the 6-membered cyclic group may optionally be further substituted;
m is 0, 1, 2, 3 or 4;
each R3 is independently a halo, —OH, —NO2, —NH2, —N3, —SH, —SO2H, —SO2NH, or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and
wherein optionally any R3, and any two adjacent carbon atoms of ring A, may together form a 4- to 12-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted.

### Claim 2 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein:
(i) ring A is monocyclic; and/or
(ii) Q is O.

### Claim 3 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R1 is a monovalent group comprising an aryl or a heteroaryl group, optionally wherein:
(i) the aryl or the heteroaryl group is monocyclic; and/or
(ii) a ring atom of the aryl group or a ring atom of the heteroaryl group is directly attached to a ring atom of ring A.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R1 is a monovalent group comprising a heterocyclic group, wherein the heterocyclic group contains at least one nitrogen atom in its ring structure, and optionally wherein:
(i) the heterocyclic group is a non-aromatic heterocyclic group; and/or (ii) the heterocyclic group is monocyclic; and/or (iii) a ring atom of the heterocyclic group is directly attached to a ring atom of ring A.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the compound is a compound of formula (Ia):
wherein R1, R2, R3, m and Q are defined in claim 1.

### Claim 11 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein each R3 is independently selected from halo; —CN; —NO2; —N3; —Rβ; —OH; —ORβ; —Rα-halo; —Rα—CN; —Rα—NO2; —Rα—N3; —R60 —Rβ; —Rα—OH; —Rα—ORβ; —SH; —SRβ; —SORβ; —SO2H; —SO2Rβ; —SO2NH2; —SO2NHRβ; —SO2N(Rβ)2; —Rα—SH; —Rα—SRβ; —Rα—SORβ; —Rα—SO2H; —Rα—SO2Rβ; —Rα—SO2NH2; —Rα—SO2NHRβ; —Rα—SO2N(Rβ)2; —NH2; —NHRβ; —N(Rβ)2; —Rα—NH2; —Rα—NHRβ; —Rα—N(Rβ)2; —CHO; —CORβ; —COOH; —COORβ; —OCORβ; —Rα—CHO; —Rα—CORβ; —Rα—COOH; —Rα—COORβ; or —Rα—OCORβ;
wherein each —Rα— is independently selected from an alkylene, alkenylene or alkynylene group, wherein the alkylene, alkenylene or alkynylene group contains from 1 to 6 atoms in its backbone, wherein one or more carbon atoms in the backbone of the alkylene, alkenylene or alkynylene group may optionally be replaced by one or more heteroatoms N, O or S, and wherein the alkylene, alkenylene or alkynylene group may optionally be substituted with one or more halo and/or —Rβ groups; and
wherein each —Rβ is independently selected from a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C2-C6 cyclic group, and wherein any —Rβ may optionally be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), —O(C3-C7 cycloalkyl), halo, —OH, —NH2, —CN, —CECH, oxo (═O), or 4- to 6-membered heterocyclic group.

### Claim 12 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the compound is a compound of formula (Ib):
wherein R1, R2 and Q are as defined in claim 1, and wherein R3 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, wherein the hydrocarbyl group includes at least one oxygen atom in its carbon skeleton, and wherein the hydrocarbyl group may optionally include one or more additional heteroatoms N or O in its carbon skeleton.

### Claim 13 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein:
(i) the substituent at the 4-position of the 6-membered cyclic group of R2 is a halo, —OH, —NO2, —NH2, —N3, —SH, —SO2H, —SO2NH, or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; or
(ii) the substituent at the 4-position of the 6-membered cyclic group of R2 is a halo, —NO2, —CN, —COOR21, —CONH2, —CONHR21 or —CON(R21)2 group, wherein each —R21 is independently selected from a C1-C4 alkyl group, and wherein any —R21 may optionally be substituted with one or more halo groups.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R2 is a phenyl or a 6-membered heteroaryl group substituted at the 2- and 4-positions, or a phenyl or a 6-membered heteroaryl group substituted at the 2-, 4- and 6-positions, wherein the phenyl or the 6-membered heteroaryl group may optionally be further substituted.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 15, wherein R2 is a fused phenyl group, wherein a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the phenyl group across the 2,3-positions and a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the phenyl group across the 5,6-positions, wherein the phenyl group is further substituted at the 4-position, and wherein R2 may optionally be further substituted.

### Claim 18 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the substituent at the 2-position of the 6-membered cyclic group of R2 is a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the monovalent heterocyclic or monovalent aromatic group is directly attached to the ring atom at the 2-position of the 6-membered cyclic group, wherein the monovalent heterocyclic or monovalent aromatic group may optionally be substituted.

### Claim 19 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R2 is a 6-membered cyclic group substituted at the 2-, 4- and 6-positions, wherein the 6-membered cyclic group may optionally be further substituted.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, and a pharmaceutically acceptable excipient.

### Claim 24 (depends on 1)

A method of treating or preventing a disease, disorder or condition in a subject, the method comprising the step of administering an effective amount of a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, to the subject, thereby treating or preventing the disease, disorder or condition, optionally wherein the disease, disorder or condition is responsive to NLRP3 inhibition.

### Claim 25

(canceled)

### Claim 26 (depends on 24)

The method as claimed in claim 24, wherein the disease, disorder or condition is selected from:
(i) inflammation;
(ii) an auto-immune disease;
(iii) cancer;
(iv) an infection;
(v) a central nervous system disease;
(vi) a metabolic disease;
(vii) a cardiovascular disease;
(viii) a respiratory disease;
(ix) a liver disease;
(x) a renal disease;
(xi) an ocular disease;
(xii) a skin disease;
(xiii) a lymphatic condition;
(xiv) a psychological disorder;
(xv) graft versus host disease; and
(xvi) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

### Claim 27 (depends on 24)

The method as claimed in claim 24, wherein the disease, disorder or condition is selected from:
(i) cryopyrin-associated periodic syndromes (CAPS);
(ii) Muckle-Wells syndrome (MWS);
(iii) familial cold autoinflammatory syndrome (FCAS);
(iv) neonatal onset multisystem inflammatory disease (NOMID);
(v) familial Mediterranean fever (FMF);
(vi) pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA);
(vii) hyperimmunoglobulinemia D and periodic fever syndrome (HIDS);
(viii) Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS);
(ix) systemic juvenile idiopathic arthritis;
(x) adult-onset Still's disease (AOSD);
(xi) relapsing polychondritis;
(xii) Schnitzler's syndrome;
(xiii) Sweet's syndrome;
(xiv) Behcet's disease;
(xv) anti-synthetase syndrome;
(xvi) deficiency of interleukin 1 receptor antagonist (DIRA); and
(xvii) haploinsufficiency of A20 (HA20).

### Claim 28 (depends on 1)

A method of inhibiting NLRP3 in a subject, the method comprising administering a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, to the subject thereby inhibiting NLRP3.

### Claim 29 (depends on 1)

A method of analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 by a compound, comprising contacting a cell or non-human animal with a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, and analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 in the cell or non-human animal by the compound.

### Claim 30 (depends on 24)

The method as claimed in claim 24, wherein the compound is administered as a pharmaceutical composition further comprising a pharmaceutically acceptable excipient.
